Methods for reducing the formation of by-products in the production of recombinant polypeptides
View Patent ↗A method for reducing the formation of a byproduct polypeptide containing an O-acetylserine residue in place of a serine residue by adding at least one of histidine, methionine or glycine to the medium in a method for producing a polypeptide containing a serine residue by culturing transformed cells, and a method for producing a polypeptide containing a serine residue by culturing transformed cells, characterized by reducing the formation of a byproduct polypeptide containing an O-acetylserine residue in place of a serine residue by adding at least one of histidine, methionine or glycine to the medium.
1. A method for producing a polypeptide comprising a serine residue comprising:
(i) culturing, in a medium, transformed host cells that produce a recombinant atrial natriuretic peptide comprising a serine residue and a byproduct polypeptide comprising an O-acetylserine residue in place of a serine residue in the atrial natriuretic peptide;
(ii) adding at least 3 g/L methionine and at least one of at least 3 g/L histidine or at least 3 g/L glycine to the medium; and
(iii) reducing the formation of said byproduct polypeptide,
wherein the formation of said byproduct polypeptide is reduced in an amount greater than or equal to 50% as compared to a control medium with no methionine, histidine, or glycine added.
2. The method of claim 1 , wherein the host cell is a prokaryotic cell or an eukaryotic cell.
3. The method of claim 2 , wherein the host cell is a microorganism.
4. The method of claim 3 , wherein the microorganism is Escherichia coli.
5. The method of claim 1 , wherein the molecular weight of the polypeptide comprising a serine residue is about 1000 to 20000 daltons.
6. The method of claim 1 , wherein the atrial natriuretic peptide is human atrial natriuretic peptide.
7. A method for producing a polypeptide comprising a serine residue comprising:
(i) culturing, in a medium, transformed host cells that produce a recombinant atrial natriuretic peptide comprising a serine residue and a byproduct polypeptide comprising an O-acetylserine residue in place of a serine residue in the atrial natriuretic peptide;
(ii) adding at least one of at least 3 g/L histidine or at least 3 g/L glycine to the medium; and
(iii) reducing the formation of said byproduct polypeptide,
wherein the formation of said byproduct polypeptide is reduced in an amount greater than or equal to 50% as compared to a control medium with no histidine or glycine added.
8. The method of claim 7 , wherein the host cell is a prokaryotic cell or an eukaryotic cell.
9. The method of claim 8 , wherein the host cell is a microorganism.
10. The method of claim 9 , wherein the microorganism is Escherichia coli.
11. The method of claim 7 , wherein the molecular weight of the polypeptide comprising a serine residue is about 1000 to 20000 daltons.
12. The method of claim 7 , wherein the atrial natriuretic peptide is human atrial natriuretic peptide.
13. The method of claim 7 , further comprising adding an the amount of methionine effective to reduce formation of a byproduct polypeptide wherein said amount is at least 3 g/L.